[分子的设计和功能化,促进药物发现]
1Faculty of Pharmaceutical Sciences, Shonan University of Medical Sciences.
概括
研究人员设计了针对维生素D受体 (VDR) 等核受体的新型配体,并开发了螺旋状来抑制VDR-协同激活剂相互作用,推动了设计药物开发.
科学领域:
- 药用化学 医学化学
- 分子生物学分子生物学
- 药物发现 药物发现 药物发现
背景情况:
- 核受体,包括维生素D受体 (VDR),在细胞调节中发挥关键作用.
- 调节核受体活性是药物开发中的一个关键策略.
- 了解蛋白质-蛋白质相互作用对于设计向治疗方法至关重要.
研究的目的:
- 设计和合成用于核受体的新型配体,特别是VDR,视网体受体和VDR突变体.
- 开发作为VDR-协同激活剂相互作用的抑制剂的状.
- 探索雌激素受体降解策略,并预测新设计药物的生物活性.
主要方法:
- 连接体的设计和合成.
- 编的短螺旋的开发.
- 蛋白质淘汰策略和选择性雌激素受体下调调器.
- 类的形态分析.
- 对于生物活性预测的in silico研究.
主要成果:
- 成功设计,合成和核受体配体的评估.
- 证明了螺旋的功能化和形状分析.
- 对潜在设计药物的生物活性进行in silico预测.
- 探索VDR-协同激活剂相互作用的抑制和雌激素受体降解.
结论:
- 该研究成功设计和合成了针对核受体的新型配体和.
- 开发的螺旋性具有作为VDR-协同激活剂相互作用抑制剂的潜力.
- 形方法为预测设计药物开发中的生物活性提供了有价值的工具.
- 这项研究通过调节核受体功能来促进向治疗的进步.
更多相关视频
相关概念视频
Drug Discovery: Overview
12.3K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
12.3K
Structure-Activity Relationships and Drug Design
1.9K
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
1.9K
Biopharmaceutical Factors Influencing Drug Product Design: Overview
383
Rational drug product design integrates knowledge of the drug’s physicochemical properties, formulation components, manufacturing techniques, and intended route of administration. Each factor influences the drug’s performance, including how it is released, absorbed, and eliminated in the body.The physicochemical properties of a drug—such as solubility, stability, and particle size—affect its compatibility with excipients and the choice of dosage form. Excipients, though...
383
Principles of Drug Action
9.1K
Drugs are chemical substances that modify biological responses by interacting with macromolecular targets such as receptors, ion channels, transporters, and enzymes. Pharmacodynamics describes the course of action of drugs leading to the physiological effect at a specific site in the body.
Drugs can be agonists or antagonists. Like the endogenous ligands, agonists always bind and activate the target to produce a cellular response. Agonist binding induces a conformational change which in turn...
Drugs can be agonists or antagonists. Like the endogenous ligands, agonists always bind and activate the target to produce a cellular response. Agonist binding induces a conformational change which in turn...
9.1K
Drug-Receptor Bonds
5.1K
Drug-receptor bonds are formed through various chemical forces when drugs interact with target cells. Covalent bonds, strong and irreversible, are exemplified by DNA-alkylating anticancer agents that inhibit cell division. However, such irreversible drug binding lacks selectivity and can modify the DNA of the surrounding healthy cells. Covalent binding often contributes to tissue toxicity, as seen with chloroform and paracetamol metabolites binding to the liver, causing hepatotoxicity.
In...
In...
5.1K
Targets for Drug Action: Overview
10.8K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
10.8K


